Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive subtype of the disease with poor clinical outcomes and limited therapeutic options. Immune checkpoint blockade (CP) has surged to the forefront of cancer therapies with widespread clinical success in a variety of cancer types. However, the percen...

Full description

Bibliographic Details
Main Authors: Alyssa Vito, Stephanie Rathmann, Natalie Mercanti, Nader El-Sayes, Karen Mossman, John Valliant
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
triple negative breast cancer
immunotherapy
immune checkpoint therapy
radionuclide therapy
Online Access:https://www.mdpi.com/1422-0067/22/9/4843

Similar Items

Similar Items